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Abstract Telomerase is a ribonucleoprotein complex
mainly composed of a reverse transcriptase catalytic sub-
unit (telomerase reverse transcriptase gene, hTERT) that
copies a template region of its RNA subunit to the end of
the telomere. For detecting telomerase activity in a tissue
specimen the TRAP assay is a relatively sensitive and
specific method, but it can be used only on fresh tissue
extracts and offers no information at the single cell
level. Immunohistochemistry (IHC) allows to detect
hTERT protein expression at an individual cell level in
human tissues. We have tested commercially available
anti-hTERT antibodies in formalin-fixed and paraffin-
embedded human tissues by IHC. Only one monoclonal
antibody (NCL-hTERT; Novacastra) was sufficiently spe-
cific and this was applied to human tissues in which
telomerase activity had been shown by TRAP assay and
hTERT mRNA expression by RT-PCR. hTERT protein
localized diffusely in the nucleoplasm and more intensely
in the nucleoli of cancer cells and proliferating normal
cells. Mitotic cells showed diffuse staining of the entire
cell. Granular cytoplasmic staining was occasionally
found in some tumor cells. In telomerase-positive tumors
not all the tumor cells showed hTERT immunoreactivity.
A significantly heterogeneous hTERT protein expression
was observed in human tumor tissues. The hTERT im-
munostaining in fixed tissues was concordant with telom-
erase activity and hTERT mRNA expression in corre-
sponding non-fixed samples. Quantitative RT-PCR of mi-
crodissected sections showed that hTERT mRNA ex-
pression was higher in cells with nuclear expression
than in those with cytoplasmic expression. Double stain-
ing with the M30 antibody showed that a subpopulation of
hTERT-negative cells is apoptotic. We conclude that: (1)
hTERT protein can be detected by IHC in fixed human
tissues, but the choice of the antibody, tissue process-
ing, and reaction conditions are critical, (2) hTERT pro-
tein localizes in the nucleoplasm, more strongly in the
nucleolus, and occasionally in the cytoplasm, (3) telom-
erase-positive tumors show significant heterogeneity of
hTERT protein expression, and (4) a subpopulation of
hTERT protein negative tumor cells is identified as apop-
totic cells.
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Introduction
Telomerase is a large complex which consists of many
components, among which two are essential for the en-
zyme activity in vivo and in vitro: hTERT protein with
reverse transcriptase activity and the RNA template for
elongating telomeres. Telomerase activity has been found
in almost all human cancer tissues and cancer cell lines
examined to date (Shay and Bacchetti 1997; Hiyama and
Hiyama 2002). However the majority of somatic cells
does not express the enzyme activity, except for stem
cells and proliferative cells in renewable tissues (Broccoli
et al. 1995; Effros and Globerson 2002). The detection of
telomerase activity is customarily performed by TRAP
(Telomeric Repeat Amplification Protocol) assay. This
assay is relatively sensitive and specific, but it is based on
detecting the enzyme activity in extracts of fresh cells or
tissues. As a consequence, the question as to whether this
activity originates from all tumor cells in a cancer or only
from a subpopulation or whether in positive normal tis-
sues this activity originates from stem cells or from pro-
liferative cells or, alternatively, from activated lympho-
cytes, can not be answered. Expression of hTERT mRNA
is very closely associated with telomerase activity in
human tumors and can be detected by RT-PCR. However,
this approach again does not offer any information at the
level of the individual cell. Therefore in situ hybridization
of hTERT mRNA and hTERC RNA and immunohisto-
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chemistry (IHC) of hTERT protein have been exploited in
order to localize telomerase expression in human tissues.
Competitive RT-PCR data have indicated that most tumor
cells contain 15,000–60,000 molecules of hTERC and
only 1–30 copies of hTERT mRNA (Yi et al. 2001). The
number of hTERC molecules allows to detect hTERC by
in situ hybridization, but it would be extremely difficult
for in situ detection of hTERT mRNA in human tissues
without a PCR amplification step. Given the availability
of a sufficient number of protein molecules, IHC might be
used for the detection of hTERT protein at an individual
cell level in fresh or processed tissue sections. IHC of
hTERT has been attempted in a variety of tumors and
nuclear staining of cancer cells was found in most of the
studies. However, unexpected hTERT-positive staining in
normal cells and in cytoplasm of tumor cells has been
observed, depending on the antibodies used (Tahara et al.
1999; Hiyama et al. 2001; Wei and Younes 2002; Kyo et
al. 2003). Accurate localization of hTERT protein in
human tissues is needed to resolve these issues and to this
end well-characterized antibodies and validated tissue
processing and IHC reaction conditions are essential.
The aim of this study was to test the specificity of
commercial anti-hTERT antibodies. With one particular
monoclonal antibody (NCL-hTERT; Novocastra) repro-
ducible and reliable immunostaining was obtained under
very strict conditions. Immunostaining results were vali-
dated using quantitative RT-PCR (in microdissected tis-
sue sections) and TRAP assay (in corresponding fresh
tissue) as corroborative evidence. IHC was then per-
formed on a variety of human tissue samples in order to
define localization of hTERT protein in human tumor and
normal tissues.
Materials and methods
Human tissues
Two groups of formalin-fixed and paraffin-embedded human tis-
sues have been used for localization of hTERT protein. The first
group consisted of various human tissues, including normal tissues
(two samples of normal bladder, two of normal kidney, two of
normal muscle, one of a placenta, and three of normal testis) and
tumor tissues (three samples of bladder cancer, three of breast
cancer, one of a kidney cancer, two of lung cancer, and two of soft
tissue sarcoma). In this group of tissues, telomerase activity and
hTERT mRNA expression had been detected in frozen samples by
TRAP assay and RT-PCR in a previous study (Guilleret et al.
2002). hTERT protein expression was examined by IHC in for-
malin-fixed adjacent tissue samples. The second group consisted of
34 cases of colorectal adenocarcinoma, including 6 well-differen-
tiated, 20 moderately differentiated, and 8 poorly differentiated
carcinomas.
Antibodies
The three polyclonal antibodies against human hTERT protein
(PC563, Oncogene, San Diego; ab177, abcam, Cambridge; Ab-2,
Calbiochem, San Diego) and a monoclonal one (NCL-hTERT,
IgG 2a, Novocastra, UK) were of commercial origin. Mouse
monoclonal antibody M30 CytoDEATH was purchased from
Roche (Mannheim, Germany).
Immunohistochemistry of hTERT
The immunohistochemical reaction with the commercial antibodies
(PC563, Ab177, Ab2, and NCL-hTERT) was first tested on two
telomerase-positive (one sample of a colorectal carcinoma and one
of a normal testis) and two telomerase-negative tissue samples (one
sample of a normal muscle and one of a normal kidney) according
to the manufacturer’s instructions and then under different antigen
retrieval protocols (Table 1). A sensitive Dako EnVision (rabbit or
mouse) kit was used as detection system. In extensive preliminary
experiments no specific and reproducible immunostaining was
obtained with PC563, Ab177, and Ab2. On the basis of these
preliminary results the monoclonal antibody NCL-hTERT was se-
lected for localization of hTERT using the sensitive Dako EnVi-
sion+System (mouse) detection system. Deparaffinized sections
were treated with 0.3% hydrogen peroxide in methanol for 15 min
at room temperature (RT) to block endogenous peroxidase activity.
Then the sections were incubated in preheated 0.01 M, pH 6.0
sodium citrate buffer for 40 min at 90C and cooled immediately
with cold running water for 10 min. After blocking with 10%
normal goat serum for 1 h at RT, the slides were subsequently
incubated overnight with NCL-hTERT diluted in Dako Antibody
Diluent with Background Reducing Components (Dako, CA) con-
taining 0.5 M NaCl at a dilution of 1:100. After extensive washing
with PBS, the slides were incubated with Dako EnVision+System
(mouse) for 30 min and developed with DAB solution (Dako). The
sections were then counterstained with hematoxylin and mounted
for microscopic examination. Negative controls included: (1) a
blank control: omission of the primary antibody; (2) a subclass-
matched monoclonal immunoglobulin control: substitution of anti-
hTERT with a monoclonal antibody of identical isotype (anti-
neurofilament 160 kDa; NCL-NF160, IgG2a; Novocastra); (3)
negative tissue controls: seven normal (two bladder, two kidney,
two muscle, and one placenta) and one tumor tissue (a sarcoma) in
which telomerase activity and hTERT mRNA expression had been
proven absent by TRAP assay and RT-PCR.
Table 1 Antigen retrieval Power or temperature Buffer 1 Buffer 2 Time (min)
Microwave 750 W Sodium citrate, 0.1 M,
pH 6.0
EDTA, 1 mM,
pH 7.5
5, 10, 15
Pressure
cooker
115C Sodium citrate, 0.1 M,
pH 6.0
EDTA, 1 mM,
pH 7.5
1, 2, 5, 10
Autoclave 121C Sodium citrate, 0.1 M,
pH 6.0
EDTA, 1 mM,
pH 7.5
10
0.05% Pronase Room temperature – – 2, 5, 10, 15
Proteinase K Room temperature – – 2, 5, 10, 15
Incubator 90C Sodium citrate, 0.1 M – 30, 40, 60
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Double staining of hTERT and M30
The tissue slides were first stained with anti-hTERT (NCL-hTERT)
as described above with a slight modification in which the incu-
bation of anti-hTERT was carried out for only 2 h at RT. The slides
were incubated with EnVision+System (mouse) for 30 min and
developed with DAB solution. After incubating overnight with
M30 diluted at 1:100 in PBS containing 1% BSA and 0.2%
Tween 20, the immunoreaction was performed by the APPAP
method. An APPAP detection kit (Dako) with fast red as substrate
was used to visualize the localization of M30 according to the
manufacturer’s instructions.
DNA-free RNA preparation from paraffin-embedded tissues
Total RNA was extracted from fixed tissues as described previously
(Guillou et al. 2001). Total RNA, 1–5 mg, was exposed to RNase-free
DNase I (3.75 U; Pharmacia Biotech) at 37C for 30 min in 40 ml of a
solution containing 40 mM TRIS-HCL (pH 7.9), 6 mM MgCl2,
10 mM CaCl2, 10 mM NaCl, 10 mM DTT, and 4 U of RNasine
(Promega, Madison, WI). The digestion was stopped by the addition
of 5 ml of a stop solution (50 mM EDTA and 1.5 M sodium acetate).
The DNA-free RNA solution was extracted with phenol–chloroform
and precipitated in ethanol in the presence of 10 mg glycogen.
RT-PCR
DNA-free total RNA, 100 ng, was separately amplified for hTERT
mRNA and b-actin mRNA in a total volume of 15 ml with the
Platinum Quantitative RT-PCR ThermoScript One-Step System
(Invitrogen, Life Technologies, Carlsbad, CA). The primers for
hTERT mRNA and b-actin mRNA amplification were: (1) hTERT:
hTERT-L5:50-CGG AAG AGT GTC TGG AGC AA-30; L6:50-
GGA TGA AGC GGA GTC TGG A-30 and (2) b-actin: b-actin-A:
50-AGG CCA ACC GCG AGA AGA TGA-30; b-actin-B: GGC
CGT GGT GGT GAA GCT GTA G-30. Reverse transcription was
done with pNd6 random primer under the conditions of 65C 5 min,
55C 25 min, and 95C 5 min, and 40 cycles were then performed
at 95C 30 s, 62C 45 s, and 72C 45 s.
Quantitative RT-PCR
Three colorectal adenocarcinomas with cytoplasmic and significant
heterogeneous nuclear expression of hTERT by IHC were chosen
for quantitative RT-PCR analysis. According to the localization of
hTERT protein detected by IHC, tissue regions with cytoplasmic
and with nuclear staining were isolated by manual microdissection
from sections consecutive to those used for hTERT immunostain-
ing. Total RNA was then extracted after microdissection and
quantitative RT-PCR was performed using the ABI PRISM
7900HT Sequence Detection System (Applied Bio-systems, Foster
City, CA). Human TATA-box binding protein (TBP) was used as
an endogenous control. The primers and probes for hTERT mRNA
and human TBP mRNA were purchased from Applied Biosystems.
The probe for hTERT was labeled with 6FAM dye-MGB and hu-
man TBP with VIC dye-MGB. DNA-free RNA, 100 ng, was am-
plified for hTERT mRNA and human TBP mRNA in separate tubes
with TaqMan One-Step RT-PCR Master Mix Reagents Kit (Ap-
plied Biosystems). The PCR amplification was performed in a 384-
well plate using the following cycling conditions: 30 min at 48C;
10 min at 95C, followed by 50 cycles for 15 s at 95C and for
1 min at 60C. The results were expressed as relative levels of
hTERT mRNA referring to a calibrator which was arbitrarily
chosen from the studied tissues because of its lowest target ex-
pression level. The amount of target, normalized to the endogenous
reference (human TBP) and relative to the calibrator is determined
by the 2DDCT, where
DDCT=[CT(hTERTunknown)CT(TBPunknown)][CT(hTERTcalibrator)
 CT(TBPcalibrator)],
as described in Sequence Detector User Bulletin 2 (Applied Bio-
systems).
Results
Reproducible immunohistochemical staining results
were obtained with only one
of four anti-hTERT antibodies (NCL-hTERT)
For optimizing the conditions of hTERT immunostaining,
the four commercial anti-hTERT antibodies (PC563,
Ab117, Ab2, and NCL-hTERT) were tested on four par-
affin-embedded tissue samples with confirmed telomerase
activity by TRAP assay (one sample of a colorectal ad-
enocarcinoma, one of a normal testis, one of a normal
muscle, and one of a normal kidney) under different
conditions of antigen retrieval (Table 1). With PC563
antibody there was almost no staining in any tissue sec-
tion, regardless of the TRAP assay results and after ap-
plication of a range of antigen retrieval conditions. The
Ab177 antibody produced exclusively cytoplasmic stain-
ing as well in telomerase-positive as in telomerase-neg-
ative tissues, which was interpreted as non-specific stain-
ing. With Ab2 antibody nuclear and cytoplasmic staining
was found in both telomerase-positive and telomerase-
negative tissues, but more strongly in the nuclei of telom-
erase-positive tumor cells. The non-specific staining in
normal smooth muscle cells and epithelial cells of kidney
was not significantly reduced by modification of the
antigen retrieval method nor by varying the incubation
conditions. In contrast, the monoclonal antibody NCL-
hTERT labeled mainly the nucleoplasm and more in-
tensely the nucleoli of tumor cells as well as the nucleoli
of spermatogonia. However, under non-optimized condi-
tions, non-specific cytoplasmic staining was observed in
both tumor and normal cells, especially in normal smooth
muscle cells. When antigen retrieval was performed as
indicated in Materials and methods at 90C for 40 min,
nuclear staining was more intense and cytoplasmic stain-
ing was significantly reduced, but background staining
of smooth muscle cells remained. To reduce this back-
ground, different concentrations of NaCl (from 0.1 to
1 M) were tested in the incubation buffer starting at a
concentration of 0.4 M. This background disappeared
entirely with increasing NaCl concentrations, but at a
concentration over 0.7 M nuclear staining was also lost.
We therefore chose a concentration of 0.5 M NaCl in
the incubation buffer as a standard condition. Under
these conditions there was no staining of the negative
tissue control sections. Substitution of NCL-hTERT with
an isotype-matched monoclonal antibody (NCL-NF160)
showed no background staining.
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hTERT protein is heterogeneously expressed in nucleoli
of some normal and most cancer tissues
hTERT staining in various human tissues is summarized
in Table 2. With the exception of the spermatogonia in
testis, a few basal cells in bladder epithelium, and the
basal part of colon crypts, all examined normal tissues
were negative. hTERT nuclear staining was observed in
tumor cells in all ten telomerase-positive tumors, but not
in the telomerase-negative sarcoma. hTERT immuno-
staining in fixed tissues was therefore concordant with
the telomerase activity and hTERT mRNA expression
determined by TRAP assay and RT-PCR in corre-
sponding fresh tissues (Table 2). hTERT immunostain-
ing localized diffusely in the nucleoplasm and more
strongly in the nucleolus (Fig. 1A–C). Diffuse cyto-
plasmic staining was found in all mitotic cells (Fig. 1D)
and granular cytoplasmic staining occasionally in sub-
populations of tumor cells (Fig. 1E). In telomerase-
positive tumors, considerable heterogeneity of hTERT
protein expression was found, as shown in Table 2.
Lymphocytes were most prominently stained in germinal
centers (Fig. 1F).
Thirty-four colon adenocarcinomas showed expres-
sion of hTERT protein. Of 34 cases, 27 (79.4%) showed
significantly heterogeneous hTERT protein expression in
the nuclei of colorectal cancer cells (Fig. 2A–C). In
general, more than 50% of tumor cells expressed hTERT,
but the percentage of positive cells varied in an indi-
vidual case between less than 5% to 95%. Mitotic cells
consistently showed diffuse staining. Granular cytoplas-
mic staining was occasionally found in 7 cases, confined
to small tumor cell subpopulations (Fig. 2D). In remnants
of adenomas adjacent to adenocarcinoma hTERT label-
ing was much weaker than in the carcinoma (Fig. 2E).
However, there was no significant difference between
carcinoma and adenoma in the percentage of labeled
cells. Staining intensity tended to increase in high grade
adenoma, but remained weaker than in tumor cells. In the
adjacent normal colon crypts, hTERT expression was
generally confined to the lower half of the crypts
(Fig. 2F).
hTERT immunostaining concurs
with hTERT mRNA expression
To verify the specificity of hTERT immunostaining in
human tissues, hTERT mRNA expression was examined
by RT-PCR in two hTERT immunopositive (a kidney
cancer and a sarcoma) and two immunonegative tissues
(a placenta and a sarcoma). The DNA-free RNA was
extracted from serial sections following those used for
hTERT immunostaining. RT-PCR detected hTERT mRNA
in the hTERT immunopositive, but not in the im-
munonegative tissues.
In order to further confirm the specificity of hTERT
immunostaining, quantitative RT-PCR was performed to
Table 2 Expression of telom-
erase activity, hTERT mRNA,
and hTERT protein in human
tissues
Case Samples Frozen tissue Formalin-fixed tissue
Telomerase
activitya
hTERT
mRNAb
hTERT labeling (%)c
Normal tissues
1 Bladder   A few cells at basic layer
2 Bladder   A few cells at basic layer
3 Kidney   –
4 Kidney   –
5 Muscle   –
6 Muscle   –
7 Placenta   –
8 Testis ++ + Spermatogonia
9 Testis +++ + Spermatogonia
10 Testis ++ + Spermatogonia
Tumor tissues
11 Bladder +  95
12 Bladder +++ + 80
13 Bladder + + 80 (70–90)
14 Breast +++ + 85
15 Breast +++ + 80 (50–90)
16 Breast ++ + 80 (60–95)
17 Kidney + + 40 (10–50)
18 Lung ++ + 50 (50–80)
19 Lung +++ + 50 (10–80)
20 Sarcoma + + 80 (50–90)
21 Sarcoma   –
a Telomerase activity by TRAP assay: +++ marked activity, ++ moderate activity, + low activity,  no
activity
b hTERT mRNA by RT-PCR: + positive,  negative
c Numbers indicate percentage of positive cells: outside brackets, average positivity; inside brackets,
regions with lowest positivity and regions with highest positivity. In case of homogeneous staining
only one value is shown
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detect hTERT mRNA expression level in three colorec-
tal adenocarcinomas with significantly heterogeneous
hTERT immunostaining. RNA was extracted by micro-
dissection from two or three regions, selecting for: (1)
strong nuclear staining; (2) weak nuclear staining; and (3)
cytoplasmic staining. Quantitative RT-PCR revealed that
the hTERT mRNA level was two to three times higher in
regions with strong nuclear staining than in regions with
weak nuclear staining or cytoplasmic staining.
Fig. 1A–F The localization of hTERT protein in human tumor
tissues. hTERT immunostaining localized diffusely in the nucleo-
plasm and more strongly in the nucleolus of tumor cells: bladder
cancer (A), breast cancer (B), and lung cancer (C). Cytoplasmic
staining was found in mitotic cells (D) and some population of
tumor cells (E). Lymphocytes were most prominently stained in
germinal centers (F)
Fig. 2A–F Expression of hTERT protein in colorectal adenocar-
cinoma. Homogeneous and heterogeneous hTERT protein expres-
sion in the nuclei of colorectal cancer cells (A–C). Granular cy-
toplasmic staining was confined to small tumor cell subpopulations
(D). In remnants of adenomas adjacent to adenocarcinoma hTERT
labeling was much weaker than in the carcinoma (E). In the adja-
cent normal colon crypts, hTERT expression was generally con-
fined to the lower half of the crypts (F)
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hTERT-negative cells are partly apoptotic
To explore the mechanisms of hTERT protein negative
tumor cells in telomerase-positive tumors, an anti-
cleaved cytokeratin antibody (M30) was applied to detect
apoptotic cells. M30 immunoreactivity localized in the
cytoplasm of some tumor cells, scattered or clustered in
distinct regions. To localize hTERT and M30 protein
in the same tissue section, double immunostaining was
performed. Almost all M30-immunoreactive cells were
hTERT negative. hTERT-positive cells were character-
istically M30 negative (Fig. 3A, B).
Discussion
For the detection of telomerase activity and the expres-
sion of the associated genes in tissues, TRAP assay and
RT-PCR are customarily used. However, these methods
do not provide any information about telomerase activa-
tion at an individual cell level. Regarding immunolocal-
ization of hTERT, conflicting results were reported, at
least partly depending on the antibodies used and the
tissue processing conditions (Tahara et al. 1999; Dhaene
et al. 2000; Hiyama et al. 2001; Yi et al. 2001; Wei and
Younes 2002; Kyo et al. 2003). In the present study
we compared four commercial anti-hTERT antibodies
(PC563, ab177, Ab2, and NCL-hTERT) in telomerase-
positive and telomerase-negative tissues by IHC. On
the basis of the results of hTERT immunostaining, the
NCL-hTERT monoclonal antibody was chosen for in-
vestigating the localization of hTERT protein in formalin-
fixed human tissues. In order to optimize conditions for
IHC of hTERT, the NCL-hTERT antibody was first tested
in telomerase-positive and telomerase-negative tissue
samples, following different antigen retrieval procedures.
The best result was obtained after incubation of the slides
in preheated sodium citrate buffer (0.01 M, pH 6.0) at
90C for 40 min and with NCL-hTERT antibody diluted
in Dako Antibody Diluent in the presence of 0.5 M NaCl.
The localization and expression of hTERT protein was
then investigated on formalin-fixed human tissue sam-
ples using the NCL-hTERT monoclonal antibody. hTERT
immunoreactivity predominantly localized in the nucleo-
plasm, more strongly in the nucleolus, of tumor cells in
various tumors. The dominant nucleolar hTERT staining
is in agreement with earlier observations (Wong et al.
2002). In this report strong nucleolar fluorescence was
observed in GFP-hTERT transfected cells in G1 phase
and a more diffuse intranuclear distribution in cells that
had progressed to late S/G2. In mitotic cells we constantly
found diffuse staining of the cell. Theoretically, nuclear
localization of hTERT is required to promote elongation
of telomere sequences. This corresponds to what Akiyama
and Wong (Wong et al. 2002; Akiyama et al. 2003) ob-
served, in that their GFP-hTERT signal became diffuse
throughout the whole cell after breakdown of the nucle-
ar envelope in mitosis. We found granular cytoplasmic
staining in subpopulations of tumor cells, generally con-
fined to small regions. We hypothesize that this might be
due to alternative splicing of hTERT, with failure of
translocation of a variant hTERT protein from the cyto-
plasm to the nucleus. Akiyama (Akiyama et al. 2003)
observed translocation of hTERT protein from cytoplasm
to nucleus and direct interaction with NF-kB p65 in
multiple myeloma cells (MM.1 s) modulated by TNFa.
NF-kB-specific inhibitors blocked TNFa-induced hTERT
nuclear translocation. We hypothesize that cytoplasmic
staining of tumor cells might be due to variant hTERT
proteins which fail to contact with NF-kB p65. We are
presently exploring this explanation by RT-PCR, focusing
on the splice variants that have been reported earlier
(Ulaner et al. 2001; Yi et al. 2001).
In normal tissues hTERT protein was only found in
spermatogonia of testis, proliferative cells in colon crypts,
and some basal cells in transitional epithelium, but not
in telomerase-negative tissues such as kidney, muscle, or
placenta. hTERT protein immunoreactivity was in agree-
ment with telomerase activity detected by TRAP assay and
hTERT mRNA expression detected by RT-PCR. These
findings support the specificity of the immunoreactivity
obtained with NCL-hTERT antibody and validate the
conditions we established for reliable IHC of hTERT
protein.
In tumor tissues usually more than 50% of the cells
were hTERT protein positive, but this percentage varied
between less than 5% and 95%. In the majority of tumors,
hTERT protein expression was rather heterogeneous.
Fig. 3A, B hTERT-negative
cells are partly apoptotic. Dou-
ble immunostaining of hTERT
and M30 showed that almost all
M30-immunoreactive cells
were hTERT negative and
hTERT-positive cells were
normally M30 negative (A, B)
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Quantitative RT-PCR showed that hTERT mRNA ex-
pression level was higher in regions with strong nuclear
staining than regions with weak nuclear staining or cy-
toplasmic staining.
We hypothesize that at least part of the hTERT protein
negative tumor cells do not cycle because they might have
entered into apoptosis. The antibody M30 CytoDEATH,
which stains a caspase-cleaved cytokeratin 18 epitope,
was used to identify apoptotic cells in colorectal cancer
tissue sections by double staining. M30-positive cells
were characteristically hTERT negative, where hTERT-
positive cells were rarely M30 positive. This observation
confirms that part of the observed heterogeneity is due to
hTERT-negative apoptotic cells. This, however, does not
offer a full explanation for hTERT heterogeneous im-
munoreactivity. Other mechanisms might be involved.
In conclusion, hTERT protein can reliably be detected
by IHC in fixed human tissues, but the choice of the
antibody and tissue processing conditions are crucial. The
sensitivity and specificity of hTERT immunoreactivity
was confirmed by concurrent RT-PCR and TRAP assay.
hTERT protein localized in the nuclei, notably nucleoli
and occasionally in the cytoplasm of tumor cells. Telom-
erase-positive tumors showed significant heterogeneity of
hTERT protein expression, part of hTERT protein nega-
tive tumor cells being in apoptosis. Additional mecha-
nisms responsible for heterogeneous hTERT expression in
telomerase-positive tumors need to be elucidated.
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